Related Experiment Video
Updated: Mar 26, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations
Paul D P Pharoah1, Honglin Song1, Ed Dicks1
1Affiliations of authors:CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory , Cambridge, UK (PDPP, HS, ED, PH, CB); Department of Preventive Medicine, Keck School of Medicine , USC/NorrisComprehensive Cancer Center, University of Southern California , CA (MPI, SAG, SJR); Peter MacCallum Cancer Centre, East Melbourne , Victoria , Australia (KA, AOCSG, DDB); Westmead Millennium Institute, Westmead Hospital , Sydney , Australia (AOCSG); The QIMR Berghofer Medical Research Institute , Brisbane , Australia (AOCSG); Gynaecology Research Unit, Hannover Medical School , Hannover , Germany (NB, TD); Radiation Oncology Research Unit, Hannover Medical School , Hannover , Germany (NB); Mother and Child Hospital , Minsk , Belarus (NB); Department of Health Science Research, Division of Epidemiology, Mayo Clinic , Rochester, MN (MSC, JMC, ELG); Department of Biostatistics, University of Kansas Medical Center , KS (BLF); Gynaecological Cancer Research Centre, Women's Cancer, Institute for Women's Health, University College London , London, UK (AGM, MW, UM); Clinics of Obstetrics and Gynaecology, Hannover Medical School , Hannover , Germany (PH); Department of Gynecological Oncology, Roswell Park Cancer Institute , Buffalo, NY (SL, SP, KO); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center , Los Angeles, CA (JL, BYK); Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine , Stanford, CA (VM, WS, ASW); Department of Cancer Prevention and Control, Roswell Park Cancer Institute , Buffalo, NY (KBM, LSC); Department of Obstetrics and Gynecology, Duke University Medical Center , Durham, NC (OCAC); Department of Biochemistry and Molecular Biology, University of Melbourne , Melbourne, Victoria , Australia (DDB); Sir Peter MacCallum Department of Oncology, University of Melbourne , Melbourne, Victoria , Australia (DDB); Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London , London, UK (DDB).
Abstract:
Mosaic truncating mutations in the protein phosphatase, Mg(2+)/Mn(2+)-dependent, 1D (PPM1D) gene have recently been reported with a statistically significantly greater frequency in lymphocyte DNA from ovarian cancer case patients compared with unaffected control patients. Using massively parallel sequencing (MPS) we identified truncating PPM1D mutations in 12 of 3236 epithelial ovarian cancer (EOC) case patients (0.37%) but in only one of 3431 unaffected control patients (0.03%) (P = .001). All statistical tests were two-sided. A combination of Sanger sequencing, pyrosequencing, and MPS data suggested that 12 of the 13 mutations were mosaic. All mutations were identified in post-chemotherapy treatment blood samples from case patients (n = 1827) (average 1234 days post-treatment in carriers) rather than from cases collected pretreatment (less than 14 days after diagnosis, n = 1384) (P = .002). These data suggest that PPM1D variants in EOC cases are primarily somatic mosaic mutations caused by treatment and are not associated with germline predisposition to EOC.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020